Oric Pharmaceuticals, Inc. - Common Stock (ORIC)
Frequently Asked Questions About Oric Pharmaceuticals, Inc. - Common Stock (ORIC)
How can investors stay updated on Oric Pharmaceuticals?
Investors can stay updated on Oric Pharmaceuticals by visiting the company's official website and subscribing to their news releases. Additionally, the company regularly posts updates on its clinical trial progress, financial reports, and strategic initiatives, which can also be found on financial news platforms and through investor relations communications.
How does Oric Pharmaceuticals approach drug resistance?
Oric Pharmaceuticals approaches drug resistance by employing a multi-faceted research strategy that includes understanding the molecular mechanisms of resistance, discovering novel drug candidates, and designing clinical trials that specifically target resistant cancer populations. This paradigm shift enables more effective treatments tailored to patients’ specific cancer profiles.
How does Oric Pharmaceuticals engage with the medical community?
Oric Pharmaceuticals engages with the medical community through collaborations with healthcare providers, participation in scientific conferences, and presenting research findings to oncology specialists. By fostering these relationships, the company aims to enhance knowledge exchange and ensure its therapies align with community needs.
How does Oric Pharmaceuticals fund its operations?
Oric Pharmaceuticals funds its operations through a combination of public offerings, private investments, and partnerships with other organizations. By strategically leveraging these funding sources, the company can sustain its research efforts, advance clinical trials, and expand its research and development capabilities.
Is Oric Pharmaceuticals publicly traded?
Yes, Oric Pharmaceuticals is a publicly traded company listed on the NASDAQ under the ticker symbol 'ORIC.' The company went public to raise capital for its ongoing research and clinical development efforts, allowing investors to participate in its mission to transform cancer treatment.
What are Oric's strategic partnerships?
Oric Pharmaceuticals has established strategic partnerships with various academic and industry organizations to advance its research and development efforts. These collaborations may focus on enhancing drug discovery, pooling resources for clinical trials, or leveraging complementary technologies to accelerate the development of innovative therapies.
What are the future plans for Oric Pharmaceuticals?
Oric Pharmaceuticals plans to continue advancing its clinical trial pipeline, focusing on bringing innovative therapies to patients suffering from cancer. The company aims to pursue additional partnerships, enhance its research capabilities, and expand its drug development programs to include additional candidate therapies targeting various forms of cancer.
What challenges does Oric Pharmaceuticals face?
Like many biotech companies, Oric Pharmaceuticals faces challenges such as the high cost of drug development, navigating complex regulatory environments, and the inherent risks of clinical trials. Successfully addressing these challenges is critical for the company to bring its innovative therapies to market and achieve its mission.
What does Oric Pharmaceuticals, Inc. do?
Oric Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company aims to overcome treatment resistance in cancer by leveraging its proprietary platform to identify new drug candidates and advance them through clinical development. Oric's pipeline includes targeted therapies and immunotherapies that are designed to treat various types of tumors.
What is Oric's approach to patient safety?
Oric Pharmaceuticals places a high priority on patient safety and engages in rigorous clinical trial protocols to monitor participants' health throughout the study process. The company adheres to strict regulatory guidelines, employing comprehensive safety assessments and transparent reporting to maintain the highest standards of patient care and ethical conduct.
What is Oric’s lead product candidate?
Oric's lead product candidate is ORIC-101, which is an oral drug designed to inhibit the activity of the glucocorticoid receptor (GR) in cancer cells. This therapy targets tumors that exploit GR to promote abnormal growth and resistance to other treatments, aiming to provide a novel treatment approach for patients with specific types of cancer.
What is the mission of Oric Pharmaceuticals?
The mission of Oric Pharmaceuticals is to transform the treatment landscape for patients with cancer by developing innovative therapies that can address resistance mechanisms and improve clinical outcomes. The company is dedicated to the science of drug resistance and aims to enhance patient survival through targeted and effective treatments.
What is the significance of ORIC-101?
ORIC-101 is significant due to its unique mechanism of action as a glucocorticoid receptor antagonist that may offer a novel treatment option for patients with cancers that exhibit resistance to standard therapies. Its development is aimed at enhancing the therapeutic options available for patients facing difficult-to-treat tumors.
What stage are Oric’s clinical trials in?
Oric Pharmaceuticals is engaged in early to mid-stage clinical trials for its product candidates. The company is actively conducting Phase 1 and Phase 2 trials for ORIC-101 and potentially other compounds in its pipeline, focusing on evaluating safety, efficacy, and optimal dosing.
What therapeutic areas does Oric focus on?
Oric Pharmaceuticals primarily focuses on cancer therapeutics, particularly addressing treatment resistance in solid tumors. The company is dedicated to uncovering new ways to improve therapy outcomes for patients facing challenging cancers that are often resistant to existing treatment options.
When was Oric Pharmaceuticals founded?
Oric Pharmaceuticals was founded in 2015. Since its inception, the company has focused on addressing unmet medical needs in oncology through the development of a novel pipeline of therapies aimed at various cancer types.
Where is Oric Pharmaceuticals headquartered?
Oric Pharmaceuticals is headquartered in San Diego, California. The location provides the company access to a vibrant biotechnology community and resources that facilitate research, development, and collaboration with other leading firms and institutions in the life sciences field.
Who are the key members of Oric’s management team?
Oric Pharmaceuticals' management team comprises experienced professionals with deep expertise in drug development and oncology. Key members typically include individuals with backgrounds in pharmaceutical research, clinical trials, biotechnology, and executive leadership, cultivating a strong environment for innovation and strategic growth.
What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?
The current price of Oric Pharmaceuticals, Inc. - Common Stock is 4.590
When was Oric Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on April 7th, 2025
What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 250.30M
How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?
Oric Pharmaceuticals, Inc. - Common Stock has 54.53M shares outstanding.